NCT06182917 Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
| NCT ID | NCT06182917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | West China Second University Hospital |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2023-10-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ovarian cancer ranks third in the incidence of gynecologic malignancies, while mortality ranks first. The tumor marker CA125 is the most concerned tumor marker in the clinical monitoring prognosis of ovarian cancer, and an elevated CA125 indicates a later stage and a worse prognosis. However about 20% of patients with ovarian cancer have low CA125 expression. Therefore, CA125 is not sensitive to some ovarian cancers with a high risk of recurrence. How to improve the diagnostic performance of these CA125-insensitive patients is a difficult problem in current research. Minimal residual disease (MRD) refers to the residual tumor components in the body of tumor patients after achieving complete remission through treatment. MRD detection is mainly achieved by liquid biopsy, and residual tumor components can be detected by circulating tumor DNA (ctDNA). This study aims to explore the value of MRD (ctDNA) in the risk assessment of CA125 non sensitive ovarian cancer populations by combining ctDNA with traditional imaging and serological tumor markers.
Eligibility Criteria
Inclusion Criteria: * Age 18-75; * Pathologically confirmed ovarian cancer; * CA125 ≤200U/ml at first diagnosis or recurrence; * Physical condition score PS ≤ 2 points; * Enough tumor samples for WES detection; * Patients and their families can understand and are willing to participate in this study and provide written informed consent. Exclusion Criteria: * Patients unable to provide sufficient tissue / blood samples for research detection; * Pregnant or lactating women; * Other diseases considered by the research doctor to affect the prognosis and survival;
Contact & Investigator
Mengpei Zhang
PRINCIPAL INVESTIGATOR
West China Second University Hospital
Frequently Asked Questions
Who can join the NCT06182917 clinical trial?
This trial is open to female participants only, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06182917 currently recruiting?
Yes, NCT06182917 is actively recruiting participants. Contact the research team at yrtt2013@163.com for enrollment information.
Where is the NCT06182917 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06182917 clinical trial?
NCT06182917 is sponsored by West China Second University Hospital. The principal investigator is Mengpei Zhang at West China Second University Hospital. The trial plans to enroll 35 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.